TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma
Preprint in bioRxiv (August 2024)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Preprint in bioRxiv (August 2024)
Article in Journal of Drug Delivery Science and Technology (May 2024)
Article in Journal of Controlled Release (February 2023)